Recombinant Factor News Today

Steven W. Pipe, MD, explores the latest developments in hemophilia A treatments and prophylactic therapies, including extended half-life agents and a groundbreaking bispecific antibody.

Explore the sequelae of nonadherence to prophylactic treatment in hemophilia A and discover strategies for enhancing treatment adherence and overcoming challenges through interdisciplinary collaborations.

Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and best practices in mitigating joint bleeds.

Sobi® will present new data at the 17th European Association of Haemophilia and Allied Disorders conference in Frankfurt from 6-9 February 2024. The studies that will be presented support Sobis...

Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, bleeding episodes, and quality of life in severe cases.

Allison Wheeler, MD, explores the transformative journey of hemophilia A treatment, from blood products to advanced recombinant factor therapies, longer half-life products, and subcutaneous injections, that have revolutionized care.

/PRNewswire/ -- Bleeding disorders are typically hereditary, with common symptoms encompassing easy bruising, frequent nosebleeds, heavy menstrual bleeding,...

A clinical trial is underway for a medication that could slow bleeding and improve the outcome in hemorrhagic stroke patients, if the drug is administered within two hours of initial

Indonesia's state pharmaceutical holding company, Biofarma Group, through its subsidiary Kimia Farma, signed a memorandum of understanding (MoU) with ...

PEGylation is covalently and non-covalently connecting polyethylene glycol polymer chains to molecules, such as treatments, medications, or vesicles. The...